ReCor's updated renal denervation system OK’d in Europe

| January 25, 2013 | Cardiovascular Business | Vascular & Endovascular

ReCor Medical's updated PARADISE (Percutaneous Renal Denervation) system has received CE Mark in Europe for treating resistant high blood pressure.

The 6 Fr over-the-wire ultrasound renal denervation device is designed to offer ultrasound therapy to reduce high blood pressure in treatment-resistant hypertension patients. The treatment parameters of Gen 2 have been enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and treating the nerves circumferentially.

The Gen 1 PARADISE system previously received CE Mark one year ago. It is the only CE-Marked system for renal denervation that is based on ultrasound, not radiofrequency energy, according to Menlo Park, Calif.-based ReCor, which developed the ultrasound system.

PARADISE is not currently available for clinical evaluation or sale in the U.S.

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business

Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Related Content

Around the web